TGTX - TG Therapeutics Inc Stock Price, Fair Value and News

17.08USD-0.10 (-0.58%)Delayed as of 08 May 2024, 03:05 pm ET

Market Summary

USD17.08-0.10

Delayedas of 08 May 2024, 03:05 pm

-0.58%

TGTX Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)
Losses in recent quarter

TGTX Stock Price

View Fullscreen

TGTX RSI Chart

TGTX Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

64.45

Price/Sales (Trailing)

9.18

EV/EBITDA

105.94

Price/Free Cashflow

130.91

TGTX Price/Sales (Trailing)

TGTX Profitability

EBT Margin

4.51%

Return on Equity

25.73%

Return on Assets

11.04%

Free Cashflow Yield

0.76%

TGTX Fundamentals

TGTX Revenue

Revenue (TTM)

289.3M

Rev. Growth (Yr)

713.46%

Rev. Growth (Qtr)

44.36%

TGTX Earnings

Earnings (TTM)

41.2M

Earnings Growth (Yr)

72.71%

Earnings Growth (Qtr)

25.73%

Breaking Down TGTX Revenue

52 Week Range

7.6335.22

(Low)(High)

Last 7 days

25.8%

Last 30 days

18.3%

Last 90 days

19.6%

Trailing 12 Months

-48.1%

How does TGTX drawdown profile look like?

TGTX Financial Health

Current Ratio

3.62

Debt/Equity

0.63

Debt/Cashflow

0.2

TGTX Investor Care

Shares Dilution (1Y)

3.45%

Diluted EPS (TTM)

0.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	289.3M	0	0	0
2023	8.6M	24.1M	189.8M	233.7M
2022	7.9M	7.0M	5.0M	2.8M
2021	907.0K	2.4M	4.4M	6.7M
2020	152.0K	152.0K	152.0K	152.0K
2019	337.0K	152.0K	152.0K	152.0K
2018	224.8K	297.5K	370.3K	443.0K
2017	283.1K	240.5K	231.5K	152.0K
2016	229.4K	290.5K	322.5K	323.0K
2015	86.9K	118.8K	150.7K	182.6K
2014	36.9K	42.9K	49.0K	55.0K
2013	53.5K	87.5K	120.6K	30.8K
2012	0	0	0	92.1K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of TG Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2024	lonial sagar	sold	-79,675	15.935	-5,000	-
Mar 12, 2024	charney laurence n	sold	-351,340	15.97	-22,000	-
Jan 06, 2024	weiss michael s	acquired	-	-	1,001,910	ceo
Jan 05, 2024	power sean a	acquired	-	-	75,000	cfo
Jan 05, 2024	charney laurence n	sold	-333,025	19.03	-17,500	-
Jan 03, 2024	power sean a	sold	-809,431	16.91	-47,867	cfo
Dec 15, 2023	power sean a	gifted	-	-	-40,000	cfo
Sep 28, 2023	hoberman kenneth	acquired	-	-	20,000	-
Sep 28, 2023	echelard yann	acquired	-	-	20,000	-
Sep 28, 2023	lonial sagar	sold	-	-	-20,000	-

Which funds bought or sold TGTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	TEACHER RETIREMENT SYSTEM OF TEXAS	reduced	-3.34	-79,000	487,000	-%
May 06, 2024	Quantbot Technologies LP	sold off	-100	-6,234	-	-%
May 06, 2024	HighTower Advisors, LLC	added	0.62	-20,000	160,000	-%
May 06, 2024	Parallel Advisors, LLC	sold off	-100	-7,430	-	-%
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-25,022	-	-%
May 06, 2024	SG Americas Securities, LLC	reduced	-25.53	-116,000	229,000	-%
May 03, 2024	HUNTINGTON NATIONAL BANK	added	43.12	2,011	9,339	-%
May 03, 2024	EMFO, LLC	unchanged	-	-21,505	174,915	0.16%
May 03, 2024	Riggs Asset Managment Co. Inc.	unchanged	-	-187	1,521	-%
May 03, 2024	VICTORY CAPITAL MANAGEMENT INC	added	13.61	3,708	320,064	-%

Are Funds Buying or Selling TGTX?

Are funds buying TGTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TGTX

No. of Funds

Unveiling TG Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	darwin global management, ltd.	2.7%	4,046,598	SC 13G/A
Feb 13, 2024	vanguard group inc	9.03%	13,670,944	SC 13G/A
Jan 26, 2024	blackrock inc.	7.1%	10,768,163	SC 13G/A
Jan 25, 2024	state street corp	5.45%	8,253,573	SC 13G/A
Apr 03, 2023	darwin global management, ltd.	7.1%	10,451,241	SC 13G
Feb 09, 2023	vanguard group inc	10.67%	15,502,764	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 03, 2023	state street corp	7.17%	10,415,161	SC 13G/A
Feb 01, 2023	blackrock inc.	6.3%	9,132,890	SC 13G/A
Oct 11, 2022	vanguard group inc	10.15%	14,746,392	SC 13G/A

Recent SEC filings of TG Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 06, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 18, 2024	PRE 14A	PRE 14A
Mar 15, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	144	Notice of Insider Sale Intent
Mar 12, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to TG Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

TG Therapeutics Inc News

Latest updates

TG Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	44.4%	63,474,000	43,970,500	165,815,000	16,074,000	7,803,000	80,000	95,000	594,000	2,016,000	2,321,000	2,030,000	1,545,000	793,000	38,000	38,000	38,000	38,000	38,000	38,000	38,000	38,000
Costs and Expenses	28.9%	72,744,000	56,456,000	51,031,000	-	44,795,000	-	35,057,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	60,748,000	44,795,000	52,143,000	35,057,000	39,535,000	68,888,000	95,269,000	87,158,000	79,036,000	89,995,000	86,820,000	85,760,000	50,883,000	50,283,000	37,998,000	60,899,000	35,582,000	34,727,000
S&GA Expenses	11.0%	34,581,000	31,153,500	32,769,000	30,715,000	28,068,000	22,505,000	14,254,000	12,638,000	20,609,000	32,412,000	34,899,000	34,017,000	26,762,000	43,859,000	35,296,000	14,434,000	14,261,000	7,055,500	2,914,000	2,716,000	2,342,000
R&D Expenses	87.5%	32,722,000	17,448,000	14,753,000	28,122,000	15,870,000	29,635,000	20,801,000	26,874,000	48,042,000	62,646,500	51,967,000	44,871,000	63,094,000	42,961,000	50,464,000	36,449,000	36,022,000	30,943,500	57,985,000	32,866,000	32,385,000
EBITDA Margin	-21.1%	0.09	0.11	-0.98	-7.78	-21.89	-67.45	-67.53	-48.84	-43.15	-51.16	-4.14	-7.34	-	-	-	-	-	-	-	-	-
Interest Expenses	-5.9%	2,288,000	2,431,000	3,713,000	3,627,000	2,844,000	2,862,000	1,648,000	3,017,000	2,664,000	1,079,000	1,038,000	1,623,000	1,898,000	1,290,500	1,610,000	2,228,000	1,201,000	1,899,000	1,537,000	1,077,000	774,000
Income Taxes	-	29,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-Infinity%	-10,678,000	-	-	-	-39,232,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-19.2%	0.05	0.06	-1.05	-8.25	-23.14	-71.22	-69.26	-50.01	-44.00	-52.04	-5.53	-10.09	-	-	-	-	-	-	-	-	-
Net Income	25.7%	-10,707,000	-14,416,000	113,930,000	-47,610,000	-39,232,000	-52,994,000	-35,818,000	-40,510,000	-69,013,000	-93,338,500	-85,637,000	-78,497,000	-90,628,000	-88,218,000	-87,163,000	-52,884,000	-51,116,000	-39,572,500	-61,930,000	-36,212,000	-35,156,000
Net Income Margin	162.5%	0.14	0.05	-0.14	-7.30	-19.66	-71.22	-47.49	-41.44	-41.26	-52.04	-77.84	-142	-	-	-	-	-	-	-	-	-
Free Cashflow	37.9%	-8,207,000	-13,210,000	83,701,000	-42,008,000	-59,905,000	-23,873,000	-34,499,000	-49,116,000	-68,696,000	-86,989,000	-67,280,000	-60,344,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	13.3%	373	330	331	221	197	194	218	252	303	380	410	481	549	626	274	295	102	163	93.00	107	118
Current Assets	13.4%	361	318	319	209	185	168	183	203	242	331	372	455	535	612	260	281	88.00	149	80.00	94.00	105
Cash Equivalents	-17.4%	77.00	93.00	151	97.00	61.00	102	110	147	186	299	327	402	472	553	254	261	52.00	114	45.00	57.00	64.00
Inventory	95.2%	78.00	40.00	34.00	30.00	27.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-30.5%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	26.1%	213	169	166	180	170	135	117	123	133	142	98.00	98.00	103	106	103	100	103	124	119	93.00	98.00
Current Liabilities	85.6%	100	54.00	58.00	73.00	63.00	53.00	36.00	43.00	55.00	65.00	88.00	88.00	92.00	88.00	78.00	68.00	63.00	84.00	80.00	56.00	61.00
Long Term Debt	1.2%	101	100	99.00	98.00	97.00	71.00	71.00	69.00	67.00	67.00	-	-	-	8.00	15.00	22.00	29.00	29.00	29.00	29.00	28.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	1.00	16.00	23.00	30.00	22.00	15.00	7.00	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	100	99.00	98.00	97.00	71.00	71.00	69.00	67.00	67.00	-	-	-	8.00	15.00	22.00	29.00	29.00	29.00	29.00	28.00
Shareholder's Equity	-0.2%	160	161	165	40.00	27.00	59.00	100	129	170	237	312	383	445	519	171	194	-	39.00	-	13.00	19.00
Retained Earnings	-0.7%	-1,525	-1,514	-1,500	-1,613	-1,566	-1,527	-1,500	-1,400	-1,400	-1,328	-1,235	-1,149	-1,100	-980	-892	-805	-752	-701	-661	600	-563
Additional Paid-In Capital	0.6%	1,685	1,675	1,665	1,654	1,594	1,586	1,575	1,567	1,568	1,566	1,547	1,533	1,517	1,500	1,063	1,000	751	740	636	613	583
Shares Outstanding	2.1%	155	151	151	151	149	146	135	135	134	132	132	132	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	3,400	-	-	-	564	-	-	-	4,936	-	-	-	2,163	-	-	-	688	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	37.9%	-8,207	-13,210	83,704	-42,005	-59,902	-23,870	-34,495	-49,116	-68,689	-86,909	-67,201	-60,169	-81,355	-52,026	-56,532	-43,834	-62,115	-30,393	-33,202	-35,860	-33,351
Share Based Compensation	-0.5%	9,339	9,385	9,184	12,541	6,823	11,058	7,000	-1,000	2,121	14,356	14,000	16,300	16,618	33,505	28,300	7,400	11,068	6,487	1,300	800	1,882
Cashflow From Investing	79.3%	-9,255	-44,755	-30,229	30,501	-6,168	16,269	-2,990	10,379	-43,671	3,288	-631	-2,475	-514	-52,076	14,911	11,205	1,450	4.00	-44.00	457	-1,135
Cashflow From Financing	1100.0%	10.00	-1.00	421	47,047	25,238	49.00	275	135	-850	55,997	-7,361	-7,162	-55.00	403,389	35,265	241,092	81.00	98,354	20,695	28,284	56,880

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TGTX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Revenue	$ 63,474	$ 7,803
Costs and expenses:
Cost of revenue	5,441	857
Research and development:
Noncash compensation	2,452	1,584
Other research and development	30,270	14,286
Total research and development	32,722	15,870
Selling, general and administrative:
Noncash compensation	6,887	5,240
Other selling, general and administrative	27,694	22,828
Total selling, general and administrative	34,581	28,068
Total costs and expenses	72,744	44,795
Operating loss	(9,270)	(36,992)
Other expense (income):
Interest expense	2,288	2,844
Other income	(880)	(604)
Total other expense (income), net	1,408	2,240
Net loss before taxes	(10,678)	(39,232)
Income taxes	29
Net loss	$ (10,707)	$ (39,232)
Basic and diluted net loss per common share (in dollars per share)	$ (0.07)	$ (0.28)
Weighted-average shares used in computing basic and diluted net loss per common share (in shares)	146,209,213	140,312,269
Product [Member]
Revenue:
Revenue	$ 50,488	$ 7,765
License [Member]
Revenue:
Revenue	$ 12,986	$ 38

TGTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 75,477	$ 92,933
Short-term investment securities	134,308	124,575
Accounts receivable, net	64,982	51,093
Inventories	77,719	39,823
Prepaid research and development and other current assets	8,095	9,519
Total current assets	360,581	317,943
Restricted cash	1,289	1,285
Long-term investment securities	1,320	0
Right of use assets	7,906	8,050
Leasehold interest, net	1,362	1,415
Equipment, net	66	95
Goodwill	799	799
Total assets	373,323	329,587
Current liabilities:
Accounts payable and accrued expenses	87,266	38,471
Other current liabilities	4,064	1,479
Lease liability – current portion	1,383	1,446
Deferred revenue - current portion	3,373	152
Accrued compensation	3,598	12,172
Total current liabilities	99,684	53,720
Deferred revenue, non-current portion	3,244	6,016
Loan payable – non-current	101,326	100,118
Lease liability – non-current	8,960	9,231
Total liabilities	213,214	169,085
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value per share (175,000,000 shares authorized, 154,607,052 and 151,465,598 shares issued, 154,565,743 and 151,424,289 shares outstanding at March 31, 2024 and December 31, 2023, respectively)	155	151
Additional paid-in capital	1,685,256	1,674,946
Treasury stock, at cost, 41,309 shares at March 31, 2024 and December 31, 2023	(234)	(234)
Accumulated deficit	(1,525,068)	(1,514,361)
Total stockholders’ equity	160,109	160,502
Total liabilities and stockholders’ equity	$ 373,323	$ 329,587

About TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

CEO	Mr. Michael S. Weiss Esq.
WEBSITE	tgtherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	244

TG Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for TG Therapeutics Inc? What does TGTX stand for in stocks?

TGTX is the stock ticker symbol of TG Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TG Therapeutics Inc (TGTX)?

As of Tue May 07 2024, market cap of TG Therapeutics Inc is 2.66 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TGTX stock?

You can check TGTX's fair value in chart for subscribers.

What is the fair value of TGTX stock?

You can check TGTX's fair value in chart for subscribers. The fair value of TG Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TG Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TGTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TG Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether TGTX is over valued or under valued. Whether TG Therapeutics Inc is cheap or expensive depends on the assumptions which impact TG Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TGTX.

What is TG Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, TGTX's PE ratio (Price to Earnings) is 64.45 and Price to Sales (PS) ratio is 9.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TGTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on TG Therapeutics Inc's stock?

In the past 10 years, TG Therapeutics Inc has provided 0.141 (multiply by 100 for percentage) rate of return.